

Supplementary

Table S1 Patient characteristics stratified by IL-17a expression before and after treatment

Characteristics	Number of patients (post treatment)			Number of patients (after treatment)		
	Low IL-17a	High IL-17a	P value	Low IL-17a	High IL-17a	P value
Age						
≤45 years	11	7	0.39	11	7	0.39
>45 years	16	20		16	20	
Menopause						
Yes	17	12	0.27	18	11	0.10
No	10	15		9	16	
ER status						
Negative	7	13	0.16	8	12	0.39
Positive	20	14		19	15	
PR status						
Negative	11	18	0.10	10	19	0.03
Positive	16	9		17	8	
HER2 status						
Negative	13	15	0.78	13	15	0.78
Positive	14	12		14	12	
Ki67 level						
Low (≤30%)	21	12	0.02	21	12	0.02
High	6	15		6	15	
Tumor size						
T0-2	24	17	0.06	25	16	0.01
T3-4	3	10		2	11	
Lymphatic stage						
N0-1	20	11	0.03	20	11	0.03
N2-3	7	16		7	16	
Metastasis						
M0	27	24	0.23	27	24	0.23
M1	0	3		0	3	

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth receptor 2.